The ongoing legal case pertaining to alleged infringement of the local patent for Novartis AG’s ceritinib in India is delicately poised, with a court making some sharp observations against the Swiss multinational, opponent Natco Pharma Ltd. and the Indian Patent Office as well.
Novartis had earlier moved the Delhi High Court seeking to restrain Natco from manufacturing and selling its version of ceritinib, after the Indian firm chose to launch the product without...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?